The groundbreaking success of Viagra undeniably transformed the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a challenging picture. While early returns were impressive, the cessation of patents and the rise of discounted alternatives have eroded market share. Therefore, a thorough analysis of curren